Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

21.03
+0.17000.81%
Pre-market: 20.85-0.1800-0.86%08:18 EDT
Volume:2.66M
Turnover:55.56M
Market Cap:2.22B
PE:-15.98
High:21.16
Open:20.56
Low:20.18
Close:20.86
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.78
T/O Rate:2.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.45
PE(LYR):-2.95

Loading ...

BUZZ-Sarepta rises after muscle disease drugs show promise in early-to-mid stage trials

Reuters
·
Mar 25

Sarepta Therapeutics Inc - Proof-of-Concept Data Show Single Dose of Srp-1001 and Srp-1003 Reduces Target Protein or Mrna

THOMSON REUTERS
·
Mar 25

Sarepta Therapeutics Inc - Majority of Adverse Events in Studies Were Mild to Moderate and Not Dose Dependent

THOMSON REUTERS
·
Mar 25

Sarepta Therapeutics Inc - Sirna Achieves High Muscle Concentrations Without Dose Limiting Toxicity for Fshd1 and Dm1

THOMSON REUTERS
·
Mar 25

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Rezolute (RZLT) and Demant (OtherWILLF)

TIPRANKS
·
Mar 25

Sarepta to present Phase 1/2 data for SRP-1001 in FSHD1 and SRP-1003 in DM1

Reuters
·
Mar 25

Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer

TIPRANKS
·
Mar 19

Sarepta provides regulatory update on Amondys 45, Vyondys 53

TIPRANKS
·
Mar 19

Sarepta plans FDA sNDA filings by end of April 2026 to seek traditional approval for AMONDYS 45 and VYONDYS 53

Reuters
·
Mar 19

Sarepta Therapeutics Inc - FDA Confirms Sarepta Can Submit Essence Study and Real-World Evidence for Sndas

THOMSON REUTERS
·
Mar 19

Sarepta Provides Regulatory Update on Amondys 45® and Vyondys 53®

THOMSON REUTERS
·
Mar 19

Sarepta Therapeutics Inc - to Submit Sndas to FDA by End of April 2026 for Traditional Approval

THOMSON REUTERS
·
Mar 19

Sarepta Therapeutics Inc: Requested a Meeting With FDA to Discuss Submitting Supplemental New Drug Applications

THOMSON REUTERS
·
Mar 19

Cantor Fitzgerald Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 17

Sarepta begins ENDEAVOR Cohort 8 trial of ELEVIDYS with sirolimus in 25 non-ambulant Duchenne patients

Reuters
·
Mar 16

Analysts’ Top Healthcare Picks: Edgewise Therapeutics (EWTX), Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 16

Sarepta Therapeutics Is Maintained at Outperform by Mizuho

Dow Jones
·
Mar 13

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT)

TIPRANKS
·
Mar 11

Sarepta Therapeutics Is Maintained at Sell by Citigroup

Dow Jones
·
Mar 10

Sarepta price target raised to $9 from $8 at Citi

TIPRANKS
·
Mar 10